Reacțiile adverseale inhibitorilor pompei protonice

Nicolae Bacinschi; Tatiana Rakovskaia; Ina Gutu

Reacțiile adverseale inhibitorilor pompei protonice

Autori

Nicolae Bacinschi Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0003-4854-5715
Tatiana Rakovskaia Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0002-5880-0591
Ina Gutu Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0002-7839-5415

Cuvinte cheie:

inhibitorii pompei protonice, siguranţă, reacții adverse

Rezumat

nhibitorii pompei protonice (IPP) au demonstrat siguranță la utilizarea pe termen scurt, dar cu raportări în creștere despre reacțiile adverse asociate cu tratamentul pe termen lung. Materiale și metode. S-au analizat circa 100 de lucrări referitoare la reacțiile adverse ale IPP, dintre care s-au selectat 33 de articole relevante. Rezultate. Analiza articolelor selectate a demonstrat o tendință în creștere a reacțiilor adverse la utilizarea IPP, cu estimarea manifestărilor clinice și a mecanismelor ce stau la baza lor. Prescrierea pe termen lung ale IPP poate fi responsabilă de dezvoltarea proceselor maligne, infecțiilor enterice, pneumoniei comunitare, afecțiunilor renale, hepatice și cardiovasculare, malabsorbției nutrienților (magneziu, fier, calciu, vitamina B12,), fracturilor, demenței. Concluzii. Prescrierea IPP pe termen lung necesită o argumentare certă a indicațiilor, dozelor și duratei tratamentului, precum și o monitorizare riguroasă a posibilelor efecte adverse.

Referințe

1. Altebainawi A.F., Alfaraj L.A., Alharbi A.A. et al. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database. In: Ther Adv Drug Saf. 2023 Feb 27;14:20420986231154075. https://doi.org/10.1177/20420986231154075

2. Castellana C., Pecere S., Furnari M. et al. Side effects of long-term use of proton pump inhibitors: practical considerations. In: Pol Arch Intern Med. 2021; 131: 541-549. https://doi.org/10.20452/pamw.15997

3. Chamniansawat S., Suksridechacin N, Thongon N. Current opinion on the regulation of small intestinal magnesium absorption. In: World J Gastroenterol. 2023 Jan 14; 29(2): 332-342. https://doi.org/10.3748/wjg.v29.i2.332

4. Chinzon D., Domingues G., Tosetto N., Perrotti M. Safety of long-term proton pump inhibitors: facts and myths. In: Arq Gastroenterol. 2022 Apr-Jun;59(2):219-225. https://doi.org/10.1590/s0004-2803.202202000-40

5. Edinoff A.N., Wu N.W., Parker K. et Al. Proton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review. In: Adv Ther. 2023 Jun;40(6):2693-2709. https://doi.org/10.1007/s12325-023-02476-3

6. Fong P., Chan S.T., Lei P.N. et al. Association of suicidal ideation and depression with the use of proton pump inhibitors in adults: a cross-sectional study. In: Sci Rep. 2022 Nov 14;12(1):19539. https://doi.org/10.1038/s41598-022-24244-z

7. Fossmark R., Martinsen T.C., Waldum H.L. Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility. In: Int J Mol Sci. 2019 Oct 21;20(20):5203. https://doi.org/10.3390/ijms20205203

8. Gommers L.M.M., Hoenderop J.G.J., de Baaij J.H.F. Mechanisms of proton pump inhibitor-induced hypomagnesemia. In: Acta Physiol (Oxf). 2022 Aug;235(4):e13846. https://doi.org/10.1111/apha.13846

9. Guo H., Zhang R, Zhang P. et al. Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis. In: Front Pharmacol. 2023 Mar 16;14:1129948. https://doi.org/10.3389/fphar.2023.1129948

10. Haastrup P.F., Thompson W., Søndergaard J., Jarbøl D.E. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. In: Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):114-121. https://doi.org/10.1111/bcpt.13023

11. Hwang S.J., Lee D.H., Koh S.J. et al. Correlation Between Proton Pump Inhibitors and the Complications of Liver Cirrhosis: A Systematic Review and Meta-Analysis. In: Turk J Gastroenterol. 2022 Jan;33(1):44-52. https://doi.org/10.5152/tjg.2022.20689

12. Jeridi D., Pellat A., Ginestet C. et al. The Safety of Long-Term Proton Pump Inhibitor Use on Cardiovascular Health: A Meta-Analysis. In: J Clin Med. 2022 Jul 15;11(14):4096. https://doi.org/10.3390/jcm11144096

13. Kiecka A., Szczepanik M. Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics. In: Pharmacol Rep. 2023. https://doi.org/10.1007/s43440-023-00489-x

14. Kim G.H. Proton Pump Inhibitor-Related Gastric Mucosal Changes. In: Gut Liver. 2021 Sep 15;15(5):646-652. https://doi.org/10.5009/gnl20036

15. Kinoshita Y, Ishimura N., Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. In: J Neurogastroenterol Motil. 2018 Apr 30;24(2):182-196. https://doi.org/10.5056/jnm18001

16. Lata T., Trautman J., Townend P., Wilson R.B. Current management of gastro-oesophageal reflux disease-treatment costs, safety profile, and effectiveness: a narrative review. In: Gastroenterol Rep (Oxf). 2023 Apr 18;11:goad008. https://doi.org/10.1093/gastro/goad008

17. Liamis G., Hoorn E.J., Florentin M., Milionis H. An overview of diagnosis and management of drug-induced hypomagnesemia. In: Pharmacol Res Perspect. 2021 Aug; 9(4): e00829. https://doi.org/10.1002/prp2.829

18. Mak L.Y., Fung J. Proton pump inhibitors in chronic liver disease: accomplice or bystander?. In: Hepatol Int 2020, 14, 299-301. https://doi.org/10.1007/s12072-020-10033-1

19. Manolis A.A., Manolis T.A., Melita H. et al. Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries? In: European Journal of Internal Medicine. 2020 February. 72; 15-26. https://doi.org/10.1016/j.ejim.2019.11.017

20. Mitra S., Hussain S., Rahman R. et al. A survey on the incidence of common musculoskeletal side effects among the patients taking long-term anti-ulcerant therapies in Bangladesh. In: Toxicology Reports. 2022, 9, 1796-1805. https://doi.org/10.1016/j.toxrep.2022.09.007

21. Morschel C.F., Mafra D., Eduardo J.C.C. The relationship between proton pump inhibitors and renal disease. In: J Bras Nefrol. 2018 Jul-Sep;40(3):301-306. https://doi.org/10.1590/2175-8239-jbn-2018-0021

22. Nehra A.K., Alexander J.A., Loftus C.G., Nehra V. Proton Pump Inhibitors: Review of Emerging Concerns. In: Mayo Clin Proc. 2018;93(2):240-246. https://doi.org/10.1016/j.mayocp.2017.10.022

23. Seah S., Tan YK., Teh K. et al. Proton-pump inhibitor use amongst patients with severe hypomagnesemia. In: Front Pharmacol. 2023 Jan 30;14:1092476. https://doi.org/10.3389/fphar.2023.1092476

24. Suriya R., Karthickeyan K. Long-term consequences of proton pump inhibitor usage: associated risks. In: Eur. Chem. Bull. 2023,12 (special issue 1, part-b), 4548-4556. doi: 10.31838/ecb/2023.12.s1-b.449.

25. Thong B.K.S., Ima-Nirwana S., Chin K.Y. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved. In: Int J Environ Res Public Health. 2019 May 5;16(9):1571. https://doi.org/10.3390/ijerph16091571

26. Vaezi M.F., Yu-Xiao Yang, Howden C.W. Complications of Proton Pump Inhibitor Therapy. In: Gastroenterology. 2017;153(1): 35-48. https://doi.org/10.1053/j.gastro.2017.04.047

27. Weersink R.A., Bouma M., Burger D.M. et al. Safe use of proton pump inhibitors in patients with cirrhosis. In: Br J Clin Pharmacol. 2018 Aug;84(8):1806-1820. https://doi.org/10.1111/bcp.13615

28. Wicinski M., Malinowski B., Puk O. et al. Possible Effects of Proton Pump Inhibitors on Hearing Loss Development In: BioMed Research International Volume. 2019, Article ID 4853695, 10p. https://doi.org/10.1155/2019/4853695

29. Yibirin M., De Oliveira D., Valera R. et al. Adverse Effects Associated with Proton Pump Inhibitor Use. In: Cureus. 2021 Jan 18;13(1):e12759.

https://doi.org/10.7759/cureus.12759

30. Zeng Y., Dai Y., Zhou Z. et al. Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database. In: Front Med (Lausanne). 2021 Nov 15;8:648164. https://doi.org/10.3389/fmed.2021.648164

31. Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Deprescraybing inhibitorov protonnoy pompy i vybor optimal'nogo preparata dannoy gruppy (po rezul'tatam nauchnogo foruma, sostoyavshegosya v ramkakh XXVI Ob"yedinennoy Rossiyskoy gastroenterologicheskoy nedeli). In: Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2020;30(6):7-18. https://doi.org/10.22416/1382-4376-2020-30-6-7-18

32. Osipenko M.F., Zhuk E.A. Ingibitory protonnoy pompy i bolezni pecheni: sovremennoye sostoyaniye voprosa. In: Consilium Medicum. Gastroenterologiya (Pril.). 2013; 1: 18-20.

33. Ostroumova O.D., Pereverzev A.P., Krasnov G.S. Vozmozhnyye nezhelatel'nyye pobochnyye reaktsii ingibitorov protonnoy pompy u bol'nykh pozhilogo i starcheskogo vozrasta. In: Lechebnoye delo. 2018. No. 4. pp. 7-18. doi: 10.24411/2071-5315-2018-12060.

34. Khomeriki N.M., Khomeriki S.G. Vozmozhna li optimizatsiya primeneniya ingibitorov protonnoy pompy v real'noy vrachebnoy praktike? In: Al'manakh klinicheskoy meditsiny. 2022. Vol. 50, No. 6. pp. 357-366. https://doi.org/10.18786/2072-0505-2022-50-051

Descărcări

Publicat

17.04.2026

Număr

Nr. 4(97) (2023): Supliment. Al V-lea Congres Național de Gastroenterologie și hepatologie din Republica Moldova

Secțiune

Articles

Licență

Această lucrare este licențiată în temeiul Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Cum cităm

[1]

Bacinschi, N. et al. 2026. Reacțiile adverseale inhibitorilor pompei protonice. Sănătate Publică, Economie şi Management în Medicină. 4(97) (Apr. 2026), 10–17.